Contract Research Services revenues grew by 10% to £2.5m against £2.3m in 2009.
Biomarker sales increased 19% year-on-year and now forms part of the newly created Personalised Medicine division.
The total comprehensive income for the financial year posted by Epistem was £290,000, or £3.3 per diluted share, compared to £83,000, or £1.0 per diluted share, for the year ago period.
Epistem chairman David Evans said that Epistem continues to build on its scientific and technical strengths as it transforms into a technology, profitable biotechnology and personalised medicine group underpinned by strong revenue growth.
“Against a backdrop of market uncertainty, Epistem remains vigilant, with the outlook for the expanding group increasingly positive,” Evans said.